Press Releases | BioNTech

28 September 2023

Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

Read on

18 September 2023

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

Read on

11 September 2023

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Read on

30 August 2023

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

Read on

14 August 2023

BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer

Read on

7 August 2023

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update

Read on

31 July 2023

BioNTech Completes Acquisition of InstaDeep

Read on

24 July 2023

BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023

Read on

29 June 2023

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

Read on

23 June 2023

Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

Read on

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.